We subsequently investigated the effects of the selective HDAC6 inhibitor WT161 on these ALL cells, focusing on its impact on proliferation, apoptosis, adhesion, migration, and the VLA-4/FAK signaling pathway. This evidence concerns the gene HDAC6 and acute lymphoblastic leukemia.